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Abstract
High-grade mucinous ovarian cancer (HGMOC) is often a misnomer as the 
majority of cases are metastatic disease with a gastro-intestinal origin. The 
standard platinum-based ovarian cancer (OC) chemotherapy regimens are often 
ineffective, and there are insufficient data to support the use of colorectal cancer 
(CRC) chemotherapy regimens due to the rarity of HGMOC. We described 
a cohort of four consecutive suspected HGMOC cases treated at the Royal 
Women’s Hospital, Melbourne in 2012. Two cases were treated as primary MOC, 
whereas the other two were considered to be metastatic CRC based on histo-
pathological and clinical evidence. From the RNAseq analysis, we identified two 
cases of HGMOC whose gene expression profiles were consistent with mucinous 
epithelial OC, one case that was treated as metastatic CRC with gene expres-
sion profile correlated with CRC and one case with neuroendocrine (NET) gene 
expression features. Interestingly, glucagon was over-expressed in this tumor 
that was subsequently confirmed by immunohistochemistry. These findings sug-
gest a rare glucagonoma-like NET appendiceal tumor that had metastasized to 
the surface of ovary and were unresponsive to CRC chemotherapy regimens. In 
summary, a carefully curated panel of expression markers and selected func-
tional genomics could provide diagnosis and treatment guidance for patients 
with possible HGMOC.
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1. Introduction
Primary mucinous epithelial ovarian cancer (mEOC) is a rare subset, 
2.7–11.9%, of epithelial ovarian cancer. The incidence for high grade mucinous 
ovarian cancer (HGMOC) is even lower [1]. More than two-thirds of primary 
HGMOC cases are misdiagnoses, which has huge implications for the outcome 
of these patients [2]. The overall 5-year survival outcome for localised primary 
mucinous ovarian cancer is over 95%, whereas the life expectancy of women 
with metastatic mucinous cancer ranges from months to years depending on the 
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organ site of the primary tumour. Primary mEOC is a unique subtype of ovarian 
neoplasm, which tends to occur in younger women, is confined to the ovaries and 
has a more indolent natural history. Primary mEOC is unlike metastatic mucinous 
epithelial cancer, which tends to occur in older women with multiple sites of 
metastasis (often both ovaries involved) and retains the biological behaviour of 
the primary tumour [3].
The poor outcome of patients with HGMOC is largely due to two main fac-
tors. Firstly, the majority of these patients have incurable advanced stage (stage 
IV) disease at diagnosis. Secondly, these tumours are largely unresponsive to the 
ovarian cancer chemotherapy regimen, in particular platinum-based chemo-
therapy regimen, as first-line and subsequent-line treatment [4]. Historically, 
mucinous ovarian cancers are treated as a single entity together with epithelial 
ovarian cancer, as seen in large clinical trials such as ICON3 [5], ICON5 [6] and 
ICON7 [7].
The distinction between primary and metastatic mucinous adenocarcinoma 
of the ovary has become a major focus given its importance in predicting out-
comes and also to allow appropriate tumour workup and treatment planning. 
The diagnosis of primary HGMOC and metastatic mucinous epithelial cancer 
remains challenging although there is now a better recognition by pathologists 
in distinguishing both subsets of cancer. Advances in imaging techniques and 
the involvement of multidisciplinary discussions are aiding in differentiating 
between primary and metastatic mEOC. In a recent retrospective analysis of 
patients enrolled into the ICON5 trial, where the patients were screened by a panel 
of experts and treated as ovarian cancer, 68% of stage III and IV HGMOC cases 
were redefined as metastasis to the surface of ovaries [8]. This was reflected in 
the poor outcomes of these patients because they had received standard ovarian 
cancer treatment as part of their adjuvant and palliative treatment. In general, 
patients with advanced mEOC should be treated as a separate entity requiring an 
alternative therapeutic approach, such as fluorouracil (5FU) based chemotherapy 
regimen [9]. Despite strong preliminary support for a change in regimen there is 
still a universal lack of evidence in directing treatment for this subset of cancer 
due to the rarity of HGMOC. A recent phase II trial comparing the use of plati-
num-based chemotherapy versus 5FU-based chemotherapy with or without the 
use of an anti-angiogenic agent (Bevacizumab) failed due to poor patient accrual. 
Interestingly, upon specialist pathology review of all cases (n = 36), 52% of mEOC 
were actually metastatic disease from elsewhere, highlighting again the diagnostic 
difficulties [10].
The molecular events leading to the development of HGMOC are largely 
unknown. Gene and protein expression analyses have been performed on well-
curated mucinous ovarian cancers to elucidate the key molecular processes allowing 
a better understanding of the tumour biology and development of biomarkers [11]. 
In a study published in 2006 by Heinzelmann-Schwarz et al., the gene expression 
profile of mEOC was distinct, compared with other subtypes of ovarian cancer, 
in particular, with serous and endometrioid ovarian cancer. mEOC was shown to 
express genes associated with mucin production and intestinal cell surface adhesion 
(e.g. LGALS4), demonstrating molecular similarity to malignant intestinal type 
epithelial cells but with key differences in gene expression, for example, lack of 
KRAS activity at the transcriptional level [11]. Perhaps surprisingly given earlier 
reports [12], mutations in p53 are observed in 64% of true primary mEOC [13]. 
HGMOC were distinguished by having more chromosomal copy number events, 
although still not as extensively genomically unstable as High Grade Serous Ovarian 
Cancer (HGSOC) [13].
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We describe in our mini-series four of nine consecutive cases who were referred 
to The Royal Women’s Hospital, Melbourne in 2012 and initially treated as primary 
HGMOC. These cases were annotated with the initial diagnostic work up, surgical 
procedure and subsequent management, which include follow-up investigations 
and systemic treatments. We performed RNAseq analysis on fresh frozen tumour 
samples from four patients who had consented for tumour tissue bio-banking under 
the Australian Ovarian Cancer Study (AOCS) platform. Within our metastatic 
HGMOC cohort, we identified one case with a gene and protein expression profile 
suggestive of a glucagonoma-like NET gastro-intestinal tumour, which was largely 
unresponsive to 5FU-based chemotherapy. This report highlights the genomic diver-
sity of HGMOC that might account for a variable outcome to treatment and also the 
potential clinical application of functional genomics in curating a panel of mutation 
and expression markers to improve diagnostic accuracy.
2. Patients and methods
2.1 Patient selection
The study group consisted of patients referred to and assessed for mEOC at 
the Department of Gynaecology, Royal Women’s Hospital (RWH) in Melbourne, 
between December 2011 and March 2013. For all patients, the diagnosis of mEOC 
was confirmed histologically and slides were reviewed by the RWH pathologists.
The Australian Ovarian Cancer Study (AOCS) was approved by Human 
Research Ethics Committees at the Peter MacCallum Cancer Centre, Queensland 
Institute of Medical Research, University of Melbourne and all participating 
hospitals. Additional approval was obtained from the Human Research Ethics 
Committees at the Royal Women’s Hospital and the Walter and Eliza Hall Institute.
Case data were obtained via the CONTRO-engined gemma database, Royal 
Women’s Hospital and the following parameters were collected: histology, age, date 
of diagnosis, stage of disease, grade, primary surgery (and outcomes), tumour 
markers (CA-125 and carcinoembryonic antigen) before and after chemotherapy, 
chemotherapy regimen, clinical outcome of patient following treatments (initial 
and subsequent lines), and date of death or last follow-up.
HGMOC cases (Grade 2 or 3) were selected for RNAseq analysis based on the 
availability of fresh frozen tumour sample collected at the time of surgery and 
patient consent to the AOCS study.
2.2 RNAseq
Fresh frozen tumour tissue was obtained from the bio-bank (AOCS) facility. 
Total RNA was isolated using the RNeasy kit (Qiagen), and Illumina polyA RNAseq 
performed according to standard protocols at Australian Genome Research Facility. 
Libraries were 50 bp single end sequenced in multiplexed pools to an average depth 
of 50 million reads.
The resulting reads were mapped with Bowtie2 to the human reference genome 
with local alignment and discarding multi-mapped reads. Reads were summarised 
to genes using HTSeq and ENSEMBL v69. Differential expression analysis was 
performed in edgeR [14], comparing the four HGMOC cases as a group (to identify 
gene expression common to all cases), and each case individually (to allow for high 
levels of heterogeneity between cases) to a panel of 16 High Grade Serous Ovarian 
Cancer (HGSOC) cases.
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The resulting list of up-regulated genes present in HGMOC was filtered for 
genes that are expressed in less than 10 anatomical systems in the eGenetics expres-
sion resource using ENSEMBL biomart [15].
3. Results
3.1 Patient characteristics
Nine patients with a histologically confirmed diagnosis of high-grade muci-
nous ovarian cancer presented at the Gynaecology Department of RWH between 
December 2011 and March 2013 (Figure 1). Three patients declined consent to 
AOCS and were therefore excluded from this study. Of the six patients who con-
sented to AOCS, one did not have fresh frozen tumour tissue stored during the 
original surgery and another case was excluded due to subsequent diagnosis of 
pseudomyxoma peritonei. RNAseq analysis was performed on the remaining four 
cases using tumour tissue snap frozen at surgery. The patients’ characteristics were 
summarised as per Table 1. Representative histology images are shown in Figure 2.
3.2 Case reports
3.2.1 Tumour 1
Patient #32, a 31-year-old woman with no significant family history of malig-
nancy, presented with a short history of increasing right iliac fossa abdominal pain. 
She previously had a CT scan 1 month earlier, which showed a large 16 cm complex 
left ovarian mass. This mass was confirmed by her pre-operative pelvic MRI scan 
with enlarged para-aortic lymph nodes below the renal artery and no other obvious 
Figure 1. 
Patients screened at Royal Women’s hospital during 2012/13 being treated as high grade mucinous epithelial 
ovarian cancer for RNA sequencing analysis.
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lesion identified. This patient underwent total abdominal hysterectomy (TAH), 
bilateral salpingo-oophorectomy (BSO) and para-aortic lymph node sampling. 
At surgery, her bowels and intra-peritoneal cavity looked normal. Her tumour 
histology was reviewed at a multi-disciplinary meeting and was diagnosed as 
grade 2 primary mEOC stage IA. She received no further systemic treatment. For 
completion of her cancer assessment, the patient underwent upper gastro-intestinal 
endoscopy and colonoscopy, which were both normal and subsequently had a PET/
CT scan that showed no evidence of metastatic disease. The patient remained alive 
and well at 5-year follow-up.
3.2.2 Tumour 2
Patient #35 was a 34-year-old woman with no previous significant background 
medical history and presented to her general practitioner with 1-month history 
of intermittent lower abdominal pain. Her initial ultra-sound scan organised by 
her general practitioner showed a large left ovarian cyst and pre-operative MRI 
scan confirmed a 18 cm complex mixed cystic lesion with a 5 cm solid component 
associated with moderate ascites. The patient underwent up-front surgery with 
TAH and BSO. Her peritoneum, abdominal organs and diaphragm appeared to be 
normal during surgery. The histopathology result confirmed high-grade mucinous 
adenocarcinoma of the ovary with no surface spread and negative lymph node 
Table 1. 
Patient characteristics.
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involvement. The tumour was stage IC given that the peritoneal washing was posi-
tive for malignant cells. Patient received adjuvant ovarian cancer chemotherapy, 
consisting of carboplatin and paclitaxel, at her local medical oncology centre. She 
Figure 2. 
Histopathology of the four cases: Representative haematoxylin and eosin stained slides presented at 10× and 20× 
magnification.
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also underwent upper gastro-intestinal endoscopy and colonoscopy as completion 
of her tumour assessment, which were normal. She remained well and alive at her 
last follow-up assessment 5 years later.
3.2.3 Tumour 3
Patient #49 was a 64-year-old woman with known type II diabetes mellitus 
who presented to her local hospital with increasing abdominal pain, nausea, 
vomiting, and urinary frequency. Her initial CT scan showed a right ovarian 
mass associated with peritoneal deposits. This was confirmed by her diagnostic 
laparoscopy that showed a 14 cm ovarian mass adherent to the left adnexa and 
pouch of Douglas associated with macroscopic tumour deposits on her anterior 
abdominal wall and omentum. The original biopsy confirmed adenocarcinoma 
favouring gastro-intestinal tumour. She underwent TAH, BSO, omentectomy 
and appendectomy. Bilateral ovarian masses were resected during her surgery 
together with appendiceal and omental nodules. The histopathology confirmed 
metastatic mucinous adenocarcinoma on both ovaries with evidence of similar 
tumour effacement of the appendix suggestive of appendiceal origin. It was noted 
by the pathologist that there was NET differentiation of her mucinous adenocar-
cinoma with immunohistochemistry staining for chromogranin and synaptophy-
sin positive. She was discharged from hospital following recovery of her surgery 
to the care of the gastro-intestinal (GI) team. Her case was discussed at the GI 
tumour board meeting and the expert opinion was to treat this as advanced stage 
(Stage IV) colorectal cancer with palliative fluorouracil (5FU) based chemother-
apy following her surgical debulking procedure. The patient had minimal residual 
disease prior to commencing her palliative chemotherapy. Her gastroscopy and 
colonoscopy performed post-operatively showed significant pathology. She 
completed 8 cycles of FOLFOX (5FU with oxaliplatin) following by single agent 
5FU until late 2014. The patient had an interval PET/CT scan performed a year 
later that showed minimal metabolic activity in known low volume metastatic 
peritoneal disease. She subsequently presented in 4–6 months later with incom-
plete bowel obstruction and radiological evidence of slow peritoneal disease 
progression. Her bowel obstruction resolved with conservative management and 
she declined further lines of systemic treatment. She received palliative radiation 
therapy to her peritoneal metastasis with some relief of abdominal symptom. She 
had multiple admissions to her local hospital in the following 12 months, with 
bowel-related complications and subsequently passed away in that year, 4 years 
following the diagnosis of her cancer having only effectively completed one line 
of systemic treatment.
3.2.4 Tumour 4
Patient #60 was a 67-year-old woman who was diagnosed with metastatic 
appendiceal mucinous adenocarcinoma of her right ovary 2 years prior to her 
re-referral with a left ovarian mass. Her initial cancer was treated with surgical 
removal of the right ovarian and appendiceal mass. Her surgery was complicated 
with extensive venous thrombo-embolic (VTE) events. She received no systemic 
treatment following her initial surgery and represented with a 12 cm mixed cystic/
solid mass arising from the left ovary based on initial imaging. She underwent 
second de-bulking surgery following insertion of an inferior vena cava filter for 
her VTE. This involved the removal of the dense left pelvic tumour mass that was 
adherent to her bowel, ureter and bladder requiring cystotomy and colostomy. 
The histopathology report confirmed evidence of adenocarcinoma with focal 
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intracytoplasmic mucin consistent with mucinous adenocarcinoma similar with the 
original diagnosis 2 years ago. The CK20 was strongly positive and associated with 
negative staining for CK7. The patient was discharged back to her original colorectal 
team for further management.
3.3 Transcriptome analysis by RNAseq
Due to the high level of heterogeneity in expression within the HGMOC group, 
significantly differentially expressed genes were not able to be detected in the 
group comparison. However, the individual tumour analyses identified a large 
number of differentially expressed genes. This large number of differentially 
expressed genes is an expected limitation of this type of analysis, as variance can 
only be estimated from the control group and there is no suppression of random 
variability as would be seen in a group of replicates. Because many of these genes 
were minimally informative, the differentially expressed genes were filtered to 
identify upregulated genes that are annotated as having organ specific expression 
and may be informative for the organ of origin. The RNAseq analysis identified 18 
genes with a restricted tissue/organ expression pattern that were differentially up 
regulated in the four tumour samples. These genes were enriched for expression in 
colon, stomach, pancreas, lung, kidney and skeletal muscle. Only two of the genes, 
LGALS4 and ERN2, are annotated as expressed in gynaecological tissues and both 
are also expressed in colonic tissue (Figure 3).
3.3.1  Primary mucinous ovarian epithelial carcinoma exhibits a gene expression 
profile distinct from metastatic mucinous epithelial carcinoma and  
high-grade serous ovarian cancer
The variable genes identified by transcript profiling revealed that the two 
primary HGMOC tumours #32 and #35, could be clearly distinguished from 
the two metastatic mEOC, tumours #49 and #60. A cluster of genes including 
PGC (encodes a digestive gastric protein), ANAX10 (encodes a calcium- and 
phospholipid-binding gastric protein), DOUX2 (encodes an oxidase enzyme 
common in thyroid and GI system) and C12orf36 (non-protein encoding RNA) 
were up regulated in both tumour #32 and tumour #35. Tumour #49 and 
tumour #60 had CDH17 (encodes a cadherin superfamily glycoprotein com-
mon in gastro-intestinal and pancreatic cells), GUCY2C (encodes for guanylyl 
cyclase enzyme found in intestinal epithelium) and SCGN (encodes a secre-
tory calcium binding protein in cell cytoplasm) genes up regulated. All four 
tumours shared in common high expression of seven genes not seen in HGSOC, 
in particular LGALS4, an intestinal surface cell adhesion molecule that is over-
expressed in intestinal carcinomas [16]. LGALS4 had previously been shown to 
be specifically expressed in mEOC [11]. However, in our cohort, this gene was 
universally expressed in all four tumours rendering it as a non-distinguishing 
gene. Interestingly, the two primary HGMOC (tumour #32 and tumour #35) 
retained some expression of PAX8 and WT1 together with KRT7/CK7 expression 
as also seen in the HGSOC control panel. The expression of PAX8 in mucinous 
epithelial ovarian cancer, and the lack of its expression in appendiceal cancers, 
has been previously described and this further supports the relevance of this 
gene expression in differentiating the organ of origin of the tumour [17]. With 
only two mEOC cases this analysis is weakly powered and heavily influenced by 
the individual cases. Analysis of a larger cohort and validation will be required to 
identify robust clinical markers.
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Figure 3. 
Heat map of the most differentially expressed genes in the four tumours analysed compared to HGSOC (top 
panel), and expression comparison of four commonly used markers (lower panel). The tissue specific expression 
of the listed genes: GCG: pancreas; REGA: GIT (D, Sm, C, R) + appendix; GUCY2C: GIT (D, Sm, C, R); 
CDH17: GIT (S, D, Sm, C, R) + appendix; SCGN: GIT (S, D, Sm, C, R) + pancreas; HNF4A: GIT (S, D, 
Sm, C, R) + liver + pancreas + appendix; VIL2: GIT + FGT; PDX1: GIT (D, S) + pancreas; LGALS4: GIT 
(S, D, S) + gallbladder + appendix; ERN2: GIT (S, D, S, C, R) + appendix; GPX2: GIT + liver + kidney; 
MUC17: GIT (D, Sm); PGC: S; ANAX10: S; DUOX2: thyroid + stomach; C12ord36: S; CLDN18: S; APOBEC1: 
Sm; KRT7/CK7: FT. cervix, uterine, liver, gallbladder, pancreas; KRT20/CK20: GIT (D, S, C, R); WT1: FGT; 
PAX8: FGT. GIT: gastro-intestinal tract; D: duodenum; S: stomach; Sm: small intestine; C: caecum; R: rectum; 
FGT: female genital tract; FT; fallopian tube.
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Figure 4. 
A. Adenocarcinoma seeding in the ovary; normal ovarian tissue (arrow), mucinous glandular component 
of adenocarcinoma (*); prominent stromal desmoplasia can be typically seen in tumours that secondarily 
involve the ovary (5× magnification); B. Adenocarcinoma in the ovary (20× magnification); C. Chromogranin 
immunohistochemical staining shows strong and diffuse reactivity (20× magnification); D. Glucagon 
immunohistochemical staining shows strong reactivity in tumour cells (20× magnification); E. Adenocarcinoma 
infiltrating the appendix (5× magnification); lumen of appendix (arrow); adenocarcinoma (*); 
F. Adenocarcinoma in the appendix (20× magnification); G. Adenocarcinoma in the appendix  
(20× magnification); H. Adenocarcinoma in the appendix (20× magnification).
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3.3.2  Identification of tumour #49 as a glucagonoma-like neuroendocrine tumour 
of likely appendiceal origin by transcriptome analysis
The RNAseq analysis identified up regulation of GCG, a gene that encodes for 
glucagon, in tumour #49. GCG accounted for ~5% of transcriptional output indi-
cating a high level of glucagon expression. The original histopathology report on the 
resected tumour confirmed evidence of NET differentiation within the mucinous 
adenocarcinoma, with positive IHC staining for chromogranin and synaptophysin. 
Our findings were returned to the original pathologist at RWH and further IHC 
for glucagon protein expression was performed. Strong glucagon staining was 
seen in the tumour cells by IHC, confirming the RNAseq findings (Figure 4). 
This “glucagonoma”-like tumour may have either a pancreatic origin or may have 
originated from the appendix as clinically implicated (Figure 4).
This patient’s case was discussed at the GI tumour board meeting, and despite 
the finding of our RNAseq analysis, it was treated as a standard colorectal cancer 
given the rarity of NET differentiated mucinous adenocarcinoma of the appendix. 
It was difficult to ascertain the full effect of CRC/5FU-based chemotherapy regimen 
on this patient given the limited line of treatment received and perceived minimal 
residual disease post-surgery. Unfortunately, the patient declined further chemo-
therapy at first progression but survived for a further 2 years receiving only pallia-
tive radiation treatment to problematic intra-abdominal lesions.
4. Discussion
True mucinous epithelial ovarian carcinomas are a rare subtype of ovarian 
cancer. In our limited case cohort, half of the mEOC seen in our institute at a given 
period of time were re-diagnosed as metastatic mucinous epithelial carcinoma. This 
posed a challenge for both the pathologists and surgical team to provide an accurate 
and timely diagnosis of the cancer and enable the delivery of optimal treatment. 
Clinical and radiological information, such as patient age, laterality of tumour, 
tumour stage and to some extent tumour marker CA125 can guide diagnosis prior 
surgery [3]. Ultimately, it is the histology of the resected tumour that allows 
accurate assessment of tumour origin based on the pattern of protein expression 
seen by IHC and morphology [8]. However, in patient #60 case, a previous history 
of appendiceal tumour should have raised the suspicious for metastatic recurrence 
of the tumour.
Our pilot RNAseq study indicated that tumours initially diagnosed as mEOC can 
be a diverse collection of disease, and that gene expression analysis has the potential 
to identify prognostically useful subsets. Categorising based on gene expression 
and identifying genetic aberrations is likely to greatly assist in selection of the 
optimal treatment for each individual patient. While RNAseq for each individual 
patient is an impractical method for tumour identification, the observations from 
this study contributed to the design of a larger study, GAMuT—Genomic Analysis 
of Mucinous Tumours, which will compare HGMOC to low grade and borderline 
cases to identify prognostic and therapeutically useful gene expression signatures 
(Australian National Health and Medical Research (NH&MRC) Funded Study—
APP1045783). This study will allow the selection of a panel of mutation and expres-
sion markers to elucidate the tumour organ of origin, thus providing some guidance 
in treatment selection.
We highlighted the identification of a very rare “glucagonoma-like” NET 
appendiceal tumour in our series of mEOC to indicate the reliability of functional 
genomics in identifying rare conditions. This diagnosis is in context with the 
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patient’s clinical findings and also with IHC proving glucagon protein expression 
only apparent after the RNA sequencing results were available. In hindsight, it is 
hard to predict if this patient would have benefited from repeated surgical resec-
tion of recurrent tumour [18], or to NET based treatment regimens, such as mTOR 
inhibition (everolimus) [19] or multiple tyrosine kinase inhibitor (sunitinib, 
pazopanib) [20, 21]. Furthermore, the patient did not exhibit glucagon syndrome 
and her glucagon serum level was never tested. Nevertheless, clinically tumour #49 
behaved like a NET tumour with slow indolent progression and localised complica-
tion. Unfortunately, in this case, the problematic tumour caused repeated bowel 
obstructive symptoms requiring multiple hospital admissions in the months leading 
up to the patient’s death.
The recognition of diversity of tumour subtypes even within a rare tumour 
population is important especially in designing clinical trials. Given the small 
number of patients available for accruement, it is vital that we accurately stratify 
patients into treatment arms and identify robust biomarkers early. A very rare 
tumour within a rare tumour subtype can pose a challenging issue in terms of being 
an outlier that would skew the outcome in a clinical trial and also in optimising 
treatment for this patient based on available evidence (which is lacking). These 
issues will need to be addressed in any clinical trials pertaining to rare cancer.
Acknowledgements
We thank Margot Osinski (Royal Women’s Hospital) for database assistance 
and AOCS: The Australian Ovarian Cancer Study Group was supported by the 
U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729. 
The AOCS also acknowledges the cooperation of the participating institutions in 
Australia and acknowledges the contribution of the study nurses, research assistants 
and all clinical and scientific collaborators to the study. The complete AOCS Study 
Group can be found at www.aocstudy.org. We would like to thank the women who 
participated in these research programs.
13
Glucagonoma Masquerading as a Mucinous Cancer of the Ovary: Lessons from Cell Biology
DOI: http://dx.doi.org/10.5772/intechopen.92554
Author details
Gwo Yaw Ho1,2,3,4,7*, Sumitra Ananda1,3,4,8, Cassandra J. Vandenberg1,4, 
Orla McNally7, Jeanne Tie1,3,4, Kylie Gorringe3,4, David Bowtell3, Jan Pyman7, 
Matthew J. Wakefield1,4 and Clare L. Scott1,3,4,5,6,7
1 Walter and Eliza Hall Institute, Parkville, Australia
2 Monash University, Melbourne, Australia
3 Peter MacCallum Cancer Centre, Melbourne, Australia
4 The University of Melbourne, Melbourne, Australia
5 Royal Melbourne Hospital, Parkville, Australia
6 Monash Medical Centre, Clayton, Australia
7 Royal Women’s Hospital, Parkville, Australia
8 Western Health, Melbourne, Australia
*Address all correspondence to: ho.g@wehi.edu.au
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
14
Gynaecological Malignancies - Updates and Advances
[1] Schiavone MB et al. Natural 
history and outcome of mucinous 
carcinoma of the ovary. American 
Journal of Obstetrics and Gynecology. 
2011;205:480.e1-480.e8
[2] Perren TJ. Mucinous epithelial 
ovarian carcinoma. Annals of Oncology. 
2016;27:i53-i57
[3] Khunamornpong S et al. Primary and 
metastatic mucinous adenocarcinomas 
of the ovary: Evaluation of the 
diagnostic approach using tumor size 
and laterality. Gynecologic Oncology. 
2006;101:152-157
[4] Pignata S et al. Activity of 
chemotherapy in mucinous epithelial 
ovarian cancer: A retrospective study. 
BMC Cancer. 2008;8:252
[5] Investigators, I.T. Paclitaxel 
plus carboplatin versus standard 
chemotherapy with either single-agent 
carboplatin or cyclophosphamide, 
doxorubicin, and cisplatin in women 
with ovarian cancer: The ICON3 
randomised trial. The Lancet. 
2002;360:505-515
[6] Bookman MA. GOG0182-ICON5: 
5-arm phase III randomized trial of 
paclitaxel (P) and carboplatin (C) vs 
combinations with gemcitabine (G),  
PEG-lipososomal doxorubicin (D), or 
topotecan (T) in patients (pts) with 
advanced-stage epithelial ovarian 
(EOC) or primary peritoneal (PPC) 
carcinoma. Journal of Clinical Oncology. 
2006:24(18_suppl):5002-5002. DOI: 
10.1200/jco.2006.24.18_suppl.5002
[7] Oza AM et al. Standard 
chemotherapy with or without 
bevacizumab for women with newly 
diagnosed ovarian cancer (ICON7): 
Overall survival results of a phase 3 
randomised trial. Lancet Oncology. 
2015;16:928-936
[8] Zaino RJ et al. Advanced stage 
mucinous adenocarcinoma of the ovary 
is both rare and highly lethal. Cancer. 
2010;117:554-562
[9] Hess V. Mucinous epithelial ovarian 
cancer: A separate entity requiring 
specific treatment. Journal of Clinical 
Oncology. 2004;22:1040-1044
[10] Gore ME et al. Multicentre trial 
of carboplatin/paclitaxel versus 
oxaliplatin/capecitabine, each with/
without bevacizumab, as first 
line chemotherapy for patients 
with mucinous epithelial ovarian 
cancer (mEOC). Journal of Clinical 
Oncology. 2015. DOI: 10.1200/
jco.2015.33.15_suppl.5528
[11] Heinzelmann-Schwarz VA et al. A 
distinct molecular profile associated 
with mucinous epithelial ovarian cancer. 
2006:1-10. DOI: 10.1038/sj.bjc.6603003
[12] Shih I-M, Kurman RJ. Ovarian 
tumorigenesis. The American Journal of 
Pathology. 2010;164:1511-1518
[13] Cheasley D et al. The molecular 
origin and taxonomy of mucinous 
ovarian carcinoma. Nature 
Communications. 2019:1-11. DOI: 
10.1038/s41467-019-11862-x
[14] Robinson MD, McCarthy DJ, 
Smyth GK. edgeR: A bioconductor 
package for differential expression 
analysis of digital gene expression data. 
Bioinformatics. 2009;26:139-140
[15] Magali R et al. Ensembl core 
software resources: Storage and 
programmatic access for DNA sequence 
and genome annotation. Database. 
2017:1-11. DOI: 10.1093/database
[16] Grotzinger C et al. LI-cadherin: 




Glucagonoma Masquerading as a Mucinous Cancer of the Ovary: Lessons from Cell Biology
DOI: http://dx.doi.org/10.5772/intechopen.92554
[17] Laury A et al. A comprehensive 
analysis of PAX8 expression in human 
epithelial tumors. The American Journal 
of Pathology. 2011;35:816
[18] Al-Faouri A, Ajarma K, 
Alghazawi S, Al-Rawabdeh S, 
Zayadeen A. Case report glucagonoma 
and glucagonoma syndrome: A case 
report with review of recent advances in 
management. Case Reports in Surgery. 
2016:1-3. DOI: 10.1155/2016/1484089
[19] Yao JC et al. Everolimus for the 
treatment of advanced, non-functional 
neuroendocrine tumours of the lung or 
gastrointestinal tract (RADIANT-4): A 
randomised, placebo-controlled, phase 
3 study. The Lancet. 2016;387:968-977
[20] Dahan L et al. Sunitinib malate 
for the treatment of pancreatic 
neuroendocrine tumors. New England 
Journal of Medicine. 2011;364:501-513
[21] Grande E et al. Pazopanib in 
pretreated advanced neuroendocrine 
tumors: A phase II, open-label trial 
of the Spanish task force Group for 
Neuroendocrine Tumors (GETNE). 
Annals of Oncology. 2015;26:1987-1993
